| 85 | 2 | 44 |
| 下载次数 | 被引频次 | 阅读次数 |
目的比较重组卵泡刺激素-β注射笔(普丽康注射笔)给药与传统重组卵泡刺激素注射液给药,对临床促排卵效率及临床疗效的影响。方法将98例患者随机化分为试验组与对照组,试验组采用重组卵泡刺激素-β注射笔给药,对照组给予传统重组卵泡刺激素注射液,使用促性腺激素释放激素激动剂(GnRHa)长方案进行促排卵治疗,获卵后进行体外受精-胚胎移植(IVF-ET),对比两组不同给药方式在获卵数、周期卵泡刺激素消耗量、启动周期妊娠率及卵巢过度刺激综合征的发生率。结果试验组与对照组患者平均年龄、不育年限、基础内分泌状态无统计学差异;但试验组与对照组相比,刺激天数分别为(8.6±1.9)d vs.(9.7±2.1)d,P=0.013;使用卵泡刺激素为(1 412±266)U vs.(1 546±356)U,P=0.007;而获卵数、MⅡ卵数、优胚数、临床妊娠率、继续妊娠率两组差异无统计学意义,分别为(9.0±6.7)个vs.(9.2±5.5)个,(7.1±2.8)个vs.(7.3±3.2)个,(4.8±0.6)个vs.(4.6±0.4)个,54.0%vs.56.2%,以及46.0%vs.45.8%。结论采用重组卵泡刺激素-β注射笔进行控制性促排卵治疗可以提高促排卵效率,与传统注射组比较,促排卵时间平均减少1d,每个周期卵泡刺激素使用量平均减少100U左右,而两组获卵数及妊娠率未见明显差异。
Abstract：Objective:To compare the efficiency of controlled ovarian stimulation(COH)of follitropinβdelivered by apen device with a conventional syringe in patients undergone IVF-ET treatment.Methods:A total of 98 patients were randomized into two groups:the patients in study group were received follitropinβby apen device,while the patients in control group were administrated follitropinβby a syringe.All patients were undergone GnRH agonist long protocol to induce multiple follicle development for in vitro fertilization and embryo transfer(IVF-ET).The number of oocyte retrieval,recombinant FSH consumption per cycle,pregnancy rate and incidence rate of ovarian hyperstimulation syndrome(OHSS)were compared between the groups.Results:There were no significant differences in patients' characteristics between the two groups,such as age,duration of infertility,basal endocrine status(P>0.05).The duration of COS was significantly shorter in the pen device group than that in conventional syringe group:[(8.6±1.9)days vs.(9.7±2.1)days](P=0.013).The amount of follitropinβused in patients of the pen device group was significantly less than that in conventional syringe group[(1 412±266)U vs.(1 546±356)U](P=0.007).However,no significant differences were found in numbers of oocyte retrieval[(9.0±6.7)vs.(9.2±5.5)],MⅡoocyte[(7.1±2.8)vs.(7.3±3.2)],good embryo[(4.8±0.6)vs.(4.6±0.4)],clinical pregnancy rate(54.0%vs.56.2%)and ongoing pregnancy rate(46.0%vs.45.8%)between the two groups(P>0.05).Conclusions:The pen device for administration of follitropinβis more efficient because of one day shorter duration and less dose of follitropinβcompared with the conventional syringe,while the efficacy,the number of oocyte retrieval and pregnancy rate are similar.
[1]Ludwig M,Felberbaum RE,Diedrich K,et al.Ovarian stimulation:from basic science to clinical application[J/OL].Reprod Biomed Online,2002,5[Suppl 1]:73-86.
[2]Trounson AO,Leeton JF,Wood C,et al.Pregnancies in humans by fertilization in vitro and embryo transfer in the controlled ovulatory cycle[J].Science,1981,212:681-682.
[3]Zegers-Hochschild F,Adamson GD,de Mouzon J,et al.The International Committee for Monitoring Assisted Reproductive Technology(ICMART)and the World Health Organization(WHO)revised glossary on ART terminology,2009[J].Hum Reprod,2009,24:2683-2687.
[4]Brown JB.Pituitary control of ovarian function-concepts derived from gonadotrophin therapy[J].Aust N Z J Obstet Gynaecol,1978,18:46-54.
[5]Baird DT.A model for follicular selection and ovulation:lessons from superovulation[J].J Steroid Biochem,1987,27:15-23.
[6]van Wely M,Kwan I,Burt AL,et al.Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles.A Cochrane review[J].Hum Reprod Update,2012,18:111.
[7]Lalioti MD.Impact of follicle stimulating hormone receptor variants in fertility[J].Curr Opin Obstet Gynecol,2011,23:158-167.
[8]Voortman G,van de Post J,Schoemaker RC,et al.Bioequivalence of subcutaneous injections of recombinant human follicle stimulating hormone(Puregon(R))by Peninjector and syringe[J].Hum Reprod,1999,14:1698-1702.
[9]Bosch E,Ezcurra D.Individualised controlled ovarian stimulation(iCOS):maximising success rates for assisted reproductive technology patients[J].Reprod Biol Endocrinol,2011,9:82.
[10]Voortman G,Mannaerts BM,Huisman JA.A dose proportionality study of subcutaneously and intramuscularly administered recombinant human follicle-stimulating hormone(Follistim*/Puregon)in healthy female volunteers[J].Fertil Steril,2000,73:1187-1193.
[11]Kang HJ,Kim CH,Ahn JW,et al.Comparison of follitropin beta administered by a pen device with follitropin beta administered by a conventional syringe in patients undergoing IVF-ET[J].Clin Exp Reprod Med,2011,38:37-41.
[12]Martin J,Dominguez F,Avila S,et al.Human endometrial receptivity:gene regulation[J].J Reprod Immunol,2002,55:131-139.
[13]Braat DD,Schutte JM,Bernardus RE,et al.Maternal death related to IVF in the Netherlands 1984-2008[J].Hum Reprod,2010,25:1782-1786.
[14]Devroey P,Boostanfar R,Koper NP,et al.A double-blind,non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol[J].Hum Reprod,2009,24:3063-3072.
基本信息:
中图分类号:R714.8
引用信息:
[1]徐彬.比较重组卵泡刺激素-β注射笔与传统注射液给药方式对临床促排卵效果的影响[J].生殖医学杂志,2014,23(09):723-727.
2014-09-15
2014-09-15